Stock News
Palatin’s Promise: A Look into Our Clinical Programs, Strategic Priorities, and Exciting Milestones Ahead
Dry Eye Disease (DED) and Other Exciting Developments in Biopharmaceutical Research In recent news, Palatin Technologies, Inc. has announced updates on their clinical programs and strategic priorities, highlighting upcoming milestones in the field of biopharmaceutical research. One of the key areas of focus for the company is Dry Eye Disease (DED), with the PL9643 MELODY-2…
Breaking News: Itafos Secures Amendment and Extension for Existing Credit Facilities!
Itafos Inc. Announces Refinancing and Amendment of Credit Facilities Exciting News for Itafos Inc. On September 9, 2024, Itafos Inc. (TSX-V: IFOS) made a significant announcement that has the potential to shape the future of the company. Itafos disclosed that it has entered into an amendment of its existing credit facilities with a syndicate of…
Get Ready to LOL: The Inside Scoop on the Latest Article You Can’t Miss!
Welcome to the Iron Drone Raider Revolution! Iron Drone Raider: The Future of Counter-Drone Technology Iron Drone Raider Systems – A Game-Changer in Military Defense When it comes to cutting-edge technology, Ondas Autonomous Systems Inc is at the forefront of innovation. With the recent announcement of their largest order ever for the Iron Drone Raider…
Unlocking the Benefits of AccessWire: A Comprehensive Guide to Maximizing Your Online Presence
CureVac Announces First Clinical Data from CVGBM Cancer Vaccine Study TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company specializing in messenger ribonucleic acid (“mRNA”) based medicines, has revealed that the initial clinical findings from their Phase 1 CVGBM cancer vaccine study in patients with resected…
Breaking News: Terns Pharmaceuticals Reports Promising Results from Phase 1 Clinical Trial of TERN-601, a Revolutionary Once-Daily Oral GLP-1R Agonist for Obesity Treatment
Positive Results from Terns Pharmaceuticals Phase 1 Trial for TERN-601 Statistically Significant Weight Loss and Well-Tolerated Drug Terns Pharmaceuticals, Inc. recently announced positive top-line data from its Phase 1 trial for TERN-601. The trial showed statistically significant mean weight loss of up to 5.5% over 28 days, with a 4.9% placebo adjustment. This is a…
Get Ready to Blast Off: MoonLake Immunotherapeutics’ Out-of-This-World Capital Markets Update on September 11th!
Welcome to MoonLake Immunotherapeutics’ Capital Markets Update! What to Expect Get ready for an exciting event as MoonLake Immunotherapeutics AG gears up to host a Capital Markets Update for investors and analysts. This live event will take place on Wednesday, September 11, 2024, from 9:00 – 10:30 EST in New York, and will feature key…
Clever, Personable, and Unconventional: Relay Therapeutics Shares Positive Interim Data for RLY-2608, Showing Significant Progression-Free Survival
Exciting Updates in the Treatment of Metastatic Breast Cancer RP2D Shows Promising Results in Metastatic Breast Cancer Patients Recently, there have been groundbreaking developments in the treatment of metastatic breast cancer, particularly in patients with PI3Kα-mutated, HR+/HER2- mutations. The latest data has shown a remarkable 9.2-month median PFS in heavily pre-treated patients who received RP2D…
Gold Strikes Gold: Lavras Gold Corp. Unearths 2.9 g/t of Gold Over 59 Metres at Fazenda do Posto Target in Brazil’s LDS Project – Plus Exciting Exploration Update!
Exciting Gold Discoveries at Fazenda do Posto Gold Target in Brazil Lavras Gold Corp. Releases Impressive Drill Results Toronto, Ontario–(Newsfile Corp. – September 9, 2024) – Lavras Gold Corp. (TSXV: LGC) (OTCQX: LGCFF) (“Lavras Gold” or the “Company”) is pleased to release the results from 12 new drillholes testing the Fazenda do Posto Gold Target,…